Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Heat shock 70 kDa protein 12A (HSPA12A) is a member of the HSP70 family of molecular chaperones, sharing conserved domain architecture but possessing a divergent ATP-binding domain. HSPA12A acts as an adapter protein for SORL1 (SorLA), delaying SORL1 internalization and affecting its subcellular localization[1][3][6]. HSPA12A expression is upregulated during adipocyte differentiation and in obesity, where it regulates adipogenesis chiefly by maintaining PPARγ expression[2]. It is also implicated in hepatocellular carcinoma by binding PCNA, regulating PCNA trimerization and thereby influencing cell proliferation[4]. Cerebral expression of HSPA12A is high, with potential involvement in neurodegeneration and psychiatric disorders. Although not currently a direct drug target, its roles in protein folding, cell differentiation, membrane trafficking, and disease pathogenesis highlight its potential clinical relevance as a biomarker or therapeutic candidate in metabolic, neurodegenerative, and oncologic contexts[2][3][4][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Heat shock 70 kDa protein 12A (HSPA12A).